Treatment of Relapsing Anal Carcinoma
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 32 (1) , 33-35
- https://doi.org/10.3109/02841869309083882
Abstract
Between 1983 and 1989, a total of 94 patients were admitted to the Norwegian Radium Hospital for primary squamous cell carcinoma (including 'basaloid' and 'cloacogenic' carcinomas) of the anal canal. Seven patients with evident distant metastases received chemotherapy, while without known distant metastases received combined chemo- and radiotherapy. Of the latter patients, 17 developed distant metastases and 11 local recurrence later on. Patients with distant metastases had a median survival of 12 months (range 3-54 months) following start of chemotherapy (cisplatin + 5-FU or mitomycin C + 5-FU). An abdominoperineal resection was performed on 9 of the 11 patients with local relapse. Of these, 6 patients were alive without evident disease after 3 years of observation.Keywords
This publication has 7 references indexed in Scilit:
- Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidityCancer, 1991
- Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canalThe American Journal of Medicine, 1989
- Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neckCancer, 1984
- Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinomaCancer, 1983
- Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinomaCancer, 1983
- Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology groupCancer, 1981
- Chemotherapy of carcinoma of the cervixGynecologic Oncology, 1977